Chargement en cours...
Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma
Introduction: Temozolomide (TMZ) is part of the standard of care for treating glioblastoma multiforme (GBM), an aggressive primary brain tumor. New approaches are needed to enhance therapeutic efficacy and reduce toxicity. GBM tumor cells are dependent on glucose and glutamine while relying heavily...
Enregistré dans:
| Publié dans: | Front Nutr |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6186985/ https://ncbi.nlm.nih.gov/pubmed/30349820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fnut.2018.00091 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|